Blue light-driven cell cycle arrest in thyroid cancer via Retinal-OPN3 complex

Area of Science:

• Biophotonics
• Molecular Biology
• Oncology

Background:

• Papillary thyroid carcinoma (PTC) is the most prevalent thyroid malignancy with increasing incidence.
• Conventional treatments like surgery and radiotherapy cause significant side effects, necessitating novel therapeutic strategies.
• There is a critical need for non-invasive treatments for PTC management.

Purpose of the Study:

• To investigate the efficacy of blue light photobiomodulation therapy (PBMT) as a non-invasive treatment for papillary thyroid carcinoma (PTC).
• To explore the role of the Retinal-OPSIN 3 (OPN3) complex in mediating cellular responses to PBMT in PTC cells.

Main Methods:

• PTC cells were exposed to blue light.
• Analysis of cellular proliferation, cell cycle progression, and protein expression.
• Investigation of the Retinal-OPSIN 3 (OPN3) complex's involvement using statistical analyses.

Main Results:

• Blue light exposure caused 11-cis-retinal to dissociate from OPN3, leading to all-trans retinal accumulation.
• This molecular change disrupted PTC cell proliferation and induced G0/G1 cell cycle arrest.
• The Retinal-OPN3 complex was identified as a key mediator, confirming thyroid cell photoreception potential.

Conclusions:

• PBMT targeting the Retinal-OPN3 complex presents a promising non-invasive therapeutic option for PTC.
• This research underscores the potential of light signal transduction in non-ocular tissues for cancer therapy.
• The study opens new avenues for developing non-invasive cancer treatments.